Friday 02 May 2025
Internal Reference Number: FOI_8560
Date Request Received: 07/04/2025 00:00:00
Date Request Replied To: 10/04/2025 00:00:00
This response was sent via: By Email
Request Summary: treatment of Haemophilia A
Request Category: Researcher
| Question Number 1: I am researching the incidence and treatment of Haemophilia A across the UK. I would greatly appreciate if you could answer to the following questions. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. | |
| Answer To Question 1: Question 1: A total of 34 Haemophilia A patients are registered to Salisbury centre, broken down by severity as follows:- 26 - mild <5 - moderate 5 - severe | |
| Question Number 2: In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (Emicizumab) - Standalone • Hemlibra (Emicizumab) in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products • Hympavzi (Marstacimab) • CEVENFACTA | |
| Answer To Question 2: Question 2 : In the last 3 months : <5 patients have been treated with Advate <5 patients have been treated with Elocta | |
| Question Number 3: For patients treated with Advate in the last three months, please provide: • The number of haemophilia A patients treated prophylactically • The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) | |
| Answer To Question 3: Question 3 : <5 Advate patients were treated for 'any other reason (e.g. Surgery, on-demand, breakthrough bleeds). | |
| Question Number 4: In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (Emicizumab) - Standalone • Hemlibra (Emicizumab) in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products • Hympavzi (Marstacimab) • CEVENFACTA | |
| Answer To Question 4: Question 4 : <5 patients with severe haemophilia have been treated in the last 3 months. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
